Parkinson's Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Parkinson's Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
January 2027 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's DiseaseNCT05916157observationalPercentage of Participants Experiencing Infusion Site Infections | — | Active, not recruiting | Jan 2027 | ≤ 164 d | 2026-05-15 |
| ABBV | AbbVie | A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/FoscarbidopaNCT07284342observationalChange from Baseline on Parkinson's Disease (PD)-related sleep disturbances in Advance Parkinson's Disease (aPD) Participants, as assessed by the Parkinson's Disease Sleep Scale - 2 (PDSS-2) | — | Recruiting | Jan 2027 | ≤ 164 d | 2026-07-31 |
| SER | Serina Therapeutics | SAD Study in Patients With Parkinson's Disease and Motor FluctuationsNCT07422675Incidence and Temporal Profile of Treatment-Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-06-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Parkinson's Disease
most recently updated first198 studies match. Showing the first 100 of 198 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corporation | $73.1B | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS RegistryNCT02071134observationalImprovement in patient's quality of life (QoL) during the study as compared with baseline | — | Recruiting | Device: Deep Brain Stimulation (DBS) | Parkinson's Disease | 1,500 | 2014-03-04 | Dec 2038 | ≤ 4,516 d | 2026-08-11 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)NCT07513441Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: Lu AF28996 | Parkinson Disease | 10 | 2026-05-26 | 2027-05-31 | in 284 d | 2026-08-10 |
| BSX | Boston Scientific Corporation | $73.1B | Deep Brain Stimulation (DBS) Retrospective Outcomes StudyNCT03664609observationalMean Change in Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline | — | Recruiting | Device: Deep Brain Stimulation | Parkinson Disease, Essential Tremor, Dystonia | 5,000 | 2019-03-12 | Dec 2028 | ≤ 864 d | 2026-08-04 |
| BSX | Boston Scientific Corporation | $73.1B | Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNSNCT06553625observationalChange in patient's quality of life (QoL) during the study as compared with baseline | — | Recruiting | Device: Radiofrequency Ablation | Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders | 200 | 2024-01-29 | Dec 2035 | ≤ 3,420 d | 2026-08-04 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/FoscarbidopaNCT07284342observationalChange from Baseline on Parkinson's Disease (PD)-related sleep disturbances in Advance Parkinson's Disease (aPD) Participants, as assessed by the Parkinson's Disease Sleep Scale - 2 (PDSS-2) | — | Recruiting | — | Advanced Parkinson's Disease | 103 | 2025-11-17 | Jan 2027 | ≤ 164 d | 2026-07-31 |
| ANVS | Annovis Bio Inc. | $77M | A Study of Buntanetap in Participants With PDNCT07284784Safety of buntanetap | Phase 2/3 | Recruiting | Drug: buntanetap/posiphen | Parkinson's Disease (PD), Deep Brain Stimulation | 500 | 2026-01-09 | Sep 2029 | ≤ 1,137 d | 2026-07-21 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in BelgiumNCT07382440observationalChange From Baseline in OFF Time (hours) as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV | — | Recruiting | — | Parkinson's Disease | 120 | 2026-03-09 | Sep 2028 | ≤ 772 d | 2026-07-10 |
| SER | Serina Therapeutics | $67M | SAD Study in Patients With Parkinson's Disease and Motor FluctuationsNCT07422675Incidence and Temporal Profile of Treatment-Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: SER-252 (PEOZ-apomorphine) · Device: enFuse | PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease | 40 | 2026-02-01 | 2027-01-31 | in 164 d | 2026-06-05 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80NCT05348785Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period | Phase 2 | Completed | Drug: BIIB122, BIIB122-Matching Placebo | Parkinson Disease | 650 | 2022-04-19 | 2026-03-09actual | — | 2026-06-04 |
| ABBV | AbbVie | $457.5B | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseaseNCT04750226Percentage of Participants with Adverse Event (AEs) | Phase 3 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 118 | 2021-02-18 | 2026-04-27actual | — | 2026-06-01 |
| ABBV | AbbVie | $457.5B | Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)NCT06916507observationalChange From Baseline in OFF Time (hours) | — | Recruiting | — | Parkinson's Disease | 125 | 2025-05-06 | Sep 2027 | ≤ 406 d | 2026-05-28 |
| DNLI | Denali Therapeutics Inc. | $3.9B | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)NCT06602193Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind period | Phase 2 | Active, not recruiting | Drug: BIIB122 225 mg · Other: BIIB122-Matching Placebo | Parkinson Disease | 50 | 2024-10-24 | Mar 2027 | ≤ 223 d | 2026-05-27 |
| ABBV | AbbVie | $457.5B | An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's DiseaseNCT05916157observationalPercentage of Participants Experiencing Infusion Site Infections | — | Active, not recruiting | — | Parkinson's Disease (PD) | 250 | 2023-11-30 | Jan 2027 | ≤ 164 d | 2026-05-15 |
| ABBV | AbbVie | $457.5B | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's DiseaseNCT04379050Percentage of Participants With Adverse Events (AE) | Phase 3 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 130 | 2020-06-08 | 2026-04-17actual | — | 2026-05-13 |
| ABBV | AbbVie | $457.5B | Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson DiseaseNCT06965374observationalChange From Baseline in Quality of Life as Measured by PD Questionnaire-39 (PDQ-39) Summary Index | — | Recruiting | — | Parkinson Disease | 270 | 2025-06-04 | Jun 2027 | ≤ 314 d | 2026-05-13 |
| ABBV | AbbVie | $457.5B | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseNCT06107426observationalChange From Baseline in OFF Time (hours) | — | Active, not recruiting | — | Parkinson's Disease (PD) | 427 | 2024-01-24 | May 2029 | ≤ 1,015 d | 2026-04-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4006896 in Healthy Participants and Participants With Parkinson's DiseaseNCT06809400Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A | Phase 1 | Recruiting | Drug: LY4006896, Placebo | Parkinson Disease | 127 | 2025-02-18 | Jan 2028 | ≤ 529 d | 2026-04-20 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor FluctuationsNCT07514858Change From Baseline to Week 19 in Daily Good ON Time Based on the Participant's Hauser Diary Entries | Phase 2 | Not yet recruiting | Drug: Lu AF28996, Placebo | Parkinson's Disease | 150 | 2026-06-30 | 2028-12-30 | in 863 d | 2026-04-07 |
| BIOA-B.ST | BioArctic AB | $3.0B | Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyNCT06671938Number of participants with adverse events (AEs) and serious adverse events (SAEs). | Phase 2 | Active, not recruiting | Drug: exidavnemab, Placebo Comparator | Parkinson Disease, Multiple System Atrophy | 38 | 2024-10-24 | 2026-08-17 | — | 2026-03-10 |
| HLUN-B.CO | H. Lundbeck A/S | — | Lu AF28996 in Participants With Parkinson's Disease (PD)NCT04291859Number of Participants with Treatment-emergent Adverse Events | Phase 1 | Completed | Drug: Lu AF28996 | Parkinson Disease | 57 | 2020-02-26 | 2025-10-14actual | — | 2026-03-06 |
| ABBV | AbbVie | $457.5B | Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson DiseaseNCT07227896observationalChange From Baseline in OFF Time (hours) as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV | — | Not yet recruiting | — | Parkinson's Disease | 100 | 2026-03-01 | Oct 2027 | ≤ 437 d | 2026-02-17 |
| ABBV | AbbVie | $457.5B | Expanded Access to TavapadonNCT07158827expanded access | — | Available | Drug: Tavapadon | Parkinson Disease | — | — | — | — | 2026-02-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's DiseaseNCT05642442results2026-01-15Change From Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score | Phase 2 | Completed | Drug: Placebo, Suvecaltamide | Parkinson Disease, Tremor | 169 | 2022-12-01 | 2024-10-23actual | — | 2026-01-15 |
| NVO | Novo Nordisk A/S | — | An Observational Study of Patients With Moderate Parkinson's DiseaseNCT05779475observationalChange in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (motor score) in OFF state | — | Enrolling by invitation | Other: No treatment given | Parkinson Disease | 96 | 2023-04-05 | 2030-03-11 | in 1,299 d | 2025-12-24 |
| ABBV | AbbVie | $457.5B | Open-label Trial in Parkinson's Disease (PD)NCT04760769Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: Tavapadon | Parkinson Disease | 992 | 2021-02-24 | 2025-12-01actual | — | 2025-12-23 |
| GANX | Gain Therapeutics, Inc. | $89M | Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's DiseaseNCT07280299Change from Baseline to Week 48 in the sum of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and Part III score [Efficacy] | Phase 2 | Not yet recruiting | Drug: Low Dose GT-02287, High Dose GT-02287, Placebo | Parkinson Disease | 111 | 2026-05-30 | 2028-06-30 | in 680 d | 2025-12-12 |
| BSX | Boston Scientific Corporation | $73.1B | Coordinated Reset Deep Brain StimulationNCT03732898Improvement in Quality of Life using new programming paradigm: PDQ-39 | Not applicable | Completed | Device: Novel Programming (nDBS), Conventional Programming (cDBS) | Parkinson's Disease (PD) | 15 | 2019-01-13 | 2025-11-12actual | — | 2025-12-11 |
| ABBV | AbbVie | $457.5B | Flexible-Dose Trial in Early Parkinson's Disease (PD)NCT04223193results2025-11-21Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score | Phase 3 | Completed | Drug: Tavapadon, Placebo | Parkinson Disease | 304 | 2020-01-06 | 2024-10-01actual | — | 2025-11-21 |
| GEHC | GE Healthcare | $33.0B | [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorNCT04265209Sensitivity and specificity by visual analysis | Phase 3 | Completed | Drug: SPECT, PET | Parkinson Disease, Essential Tremor | 152 | 2021-12-01 | 2024-08-02actual | — | 2025-11-17 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:NCT07219927observationalTitration Duration and Time to Optimized Dose | — | Recruiting | Other: Observational study | Parkinson Disease | 120 | 2025-03-31 | 2027-08-01 | in 346 d | 2025-10-22 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's DiseaseNCT03976349Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: BIIB094, Placebo | Parkinson's Disease | 62 | 2019-08-12 | 2024-08-12actual | — | 2025-09-23 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)NCT04476017results2023-06-06Part A: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | Phase 2 | Completed | Drug: SAGE-718 | Parkinson Disease, Cognitive Dysfunction | 18 | 2020-07-31 | 2022-03-25actual | — | 2025-09-15 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentNCT05318937results2025-02-06Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score | Phase 2 | Completed | Drug: SAGE-718-matching placebo, SAGE-718 | Parkinson Disease, Cognitive Dysfunction | 86 | 2022-06-06 | 2024-01-17actual | — | 2025-09-12 |
| MGTX | MeiraGTx, LLC | $1.3B | A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's ParticipantsNCT05603312results2025-09-05Incidence of Adverse Events Related to the Treatment | Phase 1/2 | Completed | Genetic: AAV-GAD Low Dose, AAV-GAD High Dose · Procedure: Sham Surgery | Parkinson's Disease | 14 | 2022-10-05 | 2024-09-06actual | — | 2025-09-05 |
| ABBV | AbbVie | $457.5B | Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's DiseaseNCT02906488observationalChange in "Off" Periods From Start of Treatment to Week 104 | — | Completed | — | Parkinson's Disease | 839 | 2016-09-12 | 2025-07-24actual | — | 2025-08-24 |
| MGTX | MeiraGTx, LLC | $1.3B | Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's DiseaseNCT05894343Number of participants with study drug-related adverse events and serious adverse events | Phase 1/2 | Active, not recruiting | Genetic: AAV-GAD | Parkinson's Disease | 13 | 2023-05-19 | Oct 2029 | ≤ 1,168 d | 2025-08-17 |
| ABBV | AbbVie | $457.5B | Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's DiseaseNCT06937034observationalMean Base Infusion Rate | — | Recruiting | — | Parkinson's Disease | 2,000 | 2025-04-14 | Dec 2025 | — | 2025-08-05 |
| ABBV | AbbVie | $457.5B | Fixed-Dose Trial in Early Parkinson's Disease (PD)NCT04201093results2025-07-28Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Phase 3 | Completed | Drug: Tavapadon, Placebo, Tavapadon | Parkinson Disease | 529 | 2019-12-13 | 2024-06-28actual | — | 2025-07-28 |
| GEHC | GE Healthcare | $33.0B | Altropane Dose for Imaging Patients With Suspected Parkinson's DiseaseNCT05636852results2025-07-15Striatal Visualization: Percentage of Participants With Correct Majority Classifications of 5-mCi Altropane Images as Determined by 5 Independent Blinded Readers | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: Altropane (123I) Injection | Parkinson Disease, Movement Disorders | 15 | 2023-04-24 | 2024-06-08actual | — | 2025-07-15 |
| GANX | Gain Therapeutics, Inc. | $89M | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's DiseaseNCT06732180Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs) | Phase 1 | Recruiting | Drug: GT-02287 | Parkinson Disease | 20 | 2025-02-21 | 2025-11-30 | — | 2025-05-06 |
| ABBV | AbbVie | $457.5B | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)NCT04542499results2025-03-25Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary) | Phase 3 | Completed | Drug: Tavapadon, Placebo | Parkinson Disease | 507 | 2020-09-23 | 2024-01-29actual | — | 2025-04-04 |
| BSX | Boston Scientific Corporation | $73.1B | Closed Loop Programming Evaluation Using External Responses for Deep Brain StimulationNCT03037398Difference in time to program between the two arms at Programming Visit | Not applicable | Completed | Device: Vercise Deep Brain Stimulation System | Parkinson Disease | 72 | 2017-01-11 | 2025-04-02actual | — | 2025-04-03 |
| LONA | LeonaBio | $73M | ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)NCT04831281results2025-03-04Global Statistical Test (GST) Score at Baseline | Phase 2 | Terminatedsponsor's stated reason: Enrollment ended early due to study design limitations. | Drug: ATH-1017, Placebo | Parkinson Disease Dementia, Dementia With Lewy Bodies | 28 | 2022-01-20 | 2023-04-19actual | — | 2025-03-04 |
| BSX | Boston Scientific Corporation | $73.1B | Cartesia eXTend 3D StudyNCT04577651results2024-03-29Change in Motor Function | Not applicable | Completed | Device: 16-contact Directional Deep Brain Stimulation | Parkinson Disease | 58 | 2020-11-02 | 2023-02-27actual | — | 2025-02-21 |
| BSX | Boston Scientific Corporation | $73.1B | Vercise Implantable Stimulator for Treating Parkinson's DiseaseNCT01221948results2015-11-13Mean Change in UPDRS III Score From Baseline in the Meds Off Condition (no Medications) to 26 Weeks Post First Lead Implantation in the Stim on/Meds Off Condition (Stimulation on and no Medications). | Phase 2 | Completed | Device: Deep Brain Stimulation | Idiopathic Parkinson's Disease | 53 | Oct 2010 | May 2013actual | — | 2025-02-05 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisNCT04292223results2025-01-14Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score | Phase 4 | Completed | Drug: Pimavanserin | Parkinson Disease Psychosis | 29 | 2020-02-10 | 2022-04-26actual | — | 2025-01-14 |
| NBIX | Neurocrine Biosciences | $15.7B | VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)NCT03562494Number of participants with treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Biological: VY-AADC02 · Other: Sham (Placebo) Surgery | Parkinson's Disease | 14 | 2018-10-17 | 2024-10-30actual | — | 2024-12-10 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseNCT03033498Maximum Observed Plasma Concentration (Cmax) of Levodopa | Phase 1 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 29 | 2017-05-17 | 2019-06-08actual | — | 2024-11-12 |
| ABBV | AbbVie | $457.5B | A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient EnvironmentNCT03374917Percentage of Participants with Infusion Site Reactions | Phase 1 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 20 | 2018-04-18 | 2019-03-04actual | — | 2024-11-12 |
| BIIB | Biogen | $31.4B | A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleNCT05418673results2024-06-26Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III | Phase 3 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: BIIB122, BIIB122-Matching Placebo | Parkinson Disease | 7 | 2022-08-26 | 2023-07-27actual | — | 2024-06-26 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001NCT00199381results2013-07-30Safety as Measured by Adverse Events | Phase 3 | Terminatedsponsor's stated reason: Additional long-term safety data no longer needed | Drug: Istradefylline | Parkinson's Disease | 504 | Oct 2005 | Oct 2008actual | — | 2024-05-17 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018NCT00199368Safety | Phase 3 | Completed | Drug: Istradefylline ( KW-6002) | Parkinson's Disease | 1,100 | Oct 2004 | Mar 2007actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseNCT00199394OFF time assessed by patient diaries at endpoint. | Phase 3 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 405 | Nov 2004 | Oct 2005actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaNCT00199407To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa. | Phase 3 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 230 | Jun 2004 | Nov 2005actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaNCT00199420To establish the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa. | Phase 3 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 580 | Jul 2004 | Nov 2005actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) PatientsNCT00199433Change from baseline in the UPDRS subscale III at endpoint. | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease, Movement Disorder Syndrome | 160 | May 2005 | Jul 2006actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaNCT00456586To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa. | Phase 2 | Completed | Drug: KW-6002 (istradefylline) | Parkinson's Disease | 180 | Apr 2002 | May 2003actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaNCT00456794Change from Baseline to Endpoint in percentage of awake time per day in an OFF state based on the subjects' valid ON/OFF Parkinson's disease diary data. | Phase 2 | Completed | Drug: Istradefylline (KW-6002) | Parkinson's Disease | 325 | Mar 2002 | Oct 2003actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyNCT00955045 | Phase 2/3 | Completed | Drug: istradefylline | Parkinson's Disease | — | Aug 2002 | Oct 2003actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseNCT01968031results2020-11-20Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12 | Phase 3 | Completed | Drug: Istradefylline 40 mg, Istradefylline 20 mg, Placebo | Idiopathic Parkinson's Disease | 613 | Oct 2013 | Oct 2016actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.NCT02174250Area under the concentration-time curve from time zero to infinity (AUC0 ∞) and Observed maximum plasma concentration (Cmax) of istradefylline | Phase 1 | Completed | Drug: Istradefylline 40 mg, Rifampin 300mg BID + istradefylline 40mg Day 8 only | Parkinson's Disease | 20 | Jun 2014 | Aug 2014actual | — | 2024-04-25 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseNCT02610231results2019-12-13Evaluation of the Long-term Safety and Tolerability of Oral Istradefylline (20mg or 40mg/Day [mg/d]) | Phase 3 | Completed | Drug: Istradefylline 20 mg or 40 mg | Idiopathic Parkinson's Disease | 239 | Dec 2015 | 2017-12-20actual | — | 2024-04-25 |
| VNDA | Vanda Pharmaceuticals | $329M | A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease PsychosisNCT05344365Assessment of safety and tolerability of iloperidone in patients with Parkinson's disease psychosis. | Phase 2 | Withdrawnsponsor's stated reason: Study was terminated for business reasons; not due to safety or efficacy concerns. | Drug: Iloperidone | Parkinson Disease Psychosis | 0 | Jun 2022 | Nov 2023 | — | 2024-03-21 |
| NVS | Novartis | — | An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United StatesNCT00237263Incidence of adverse events during the long term treatment (maximum 3 years) | Phase 2 | Completed | Drug: Entacapone | Parkinson's Disease | 285 | Feb 2003 | Jul 2007actual | — | 2024-01-11 |
| NBIX | Neurocrine Biosciences | $15.7B | Observational, Long-term Extension Study for Participants of Prior VY-AADC01 StudiesNCT03733496observationalIncidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | — | Completed | — | Parkinson's Disease | 14 | 2018-08-24 | 2023-07-18actual | — | 2023-12-22 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)NCT06004180Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: Lu AF28996 | Parkinson Disease | 6 | 2023-09-12 | 2023-11-21actual | — | 2023-12-11 |
| BIIB | Biogen | $31.4B | A Study to Evaluate SAGE-217 in Participants With Parkinson's DiseaseNCT03000569results2020-11-23Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A | Phase 2 | Completed | Drug: SAGE-217, Levodopa, Antiparkinsonian Agent(s) | Parkinson Disease | 29 | 2016-11-30 | 2017-09-11actual | — | 2023-11-29 |
| ABBV | AbbVie | $457.5B | A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)NCT02549092results2021-06-03Change From Baseline to Week 26 in the NMSS Total Score | Phase 3 | Completed | Drug: Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel · Device: Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube | Advanced Parkinson's Disease | 89 | 2015-10-26 | 2020-05-14actual | — | 2023-11-28 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)NCT03781167results2023-10-23Number of Participants With Adverse Events | Phase 3 | Completed | Drug: ABBV-951 | Parkinson's Disease (PD) | 244 | 2019-04-29 | 2022-08-17actual | — | 2023-10-23 |
| PFE | Pfizer | $155.3B | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's DiseaseNCT02373072Number and proportion of subjects with Adverse Events (AEs) | Phase 1 | Completed | Drug: PF-06649751, Trimethobenzamide Hydrochloride, Placebo | Idiopathic Parkinson Disease | 18 | Mar 2015 | Feb 2016actual | — | 2023-09-22 |
| BIIB | Biogen | $31.4B | BIIB014 Phase 2a MonotherapyNCT00451815 | Phase 2 | Withdrawn | Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily., placebo | Parkinson's Disease | 0 | — | — | — | 2023-08-23 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease PatientsNCT02073981observationalChanging of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | — | Completed | — | Parkinson Disease | 1,021 | Mar 2014 | May 2016actual | — | 2023-08-07 |
| PFE | Pfizer | $155.3B | PF-06669571 In Subjects With Idiopathic Parkinson's DiseaseNCT02565628results2017-08-07Maximum Percent Change From Baseline in Movement Disorder Society-Sponsor Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Day 7. | Phase 1 | Completed | Drug: PF-06669571, Placebo | Idiopathic Parkinson's Disease | 20 | 2015-11-16 | 2016-05-13actual | — | 2023-07-24 |
| BSX | Boston Scientific Corporation | $73.1B | Deep Brain Stimulation (DBS) for the Treatment of Parkinson's DiseaseNCT01839396results2018-08-15Change in ON Time as Measured by Parkinson's Disease Diary | Not applicable | Completed | Device: Deep Brain Stimulation | Parkinson's Disease | 313 | 2013-05-17 | 2016-12-27actual | — | 2023-07-13 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)NCT03944785results2021-02-18observationalChange From Baseline in Movement Disorders Society -Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | — | Completed | Drug: XADAGO (safinamide) | Idiopathic Parkinson Disease | 164 | 2017-11-30 | 2019-12-23actual | — | 2023-06-07 |
| BIIB | Biogen | $31.4B | Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseNCT04056689Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: DNL151, Placebo | Parkinson's Disease | 36 | 2019-07-23 | 2020-12-02actual | — | 2023-04-18 |
| SER | Serina Therapeutics | $67M | A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214NCT02579473Safety - Adverse Events and Serious Adverse Events | Phase 1 | Unknown status | Drug: SER-214 | Parkinson's Disease | 20 | Jan 2016 | 2023-12-31 | — | 2023-04-11 |
| ABBV | AbbVie | $457.5B | Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's DiseaseNCT05094050Maximum Observed Plasma Concentration (Cmax) of Levodopa (LD) | Phase 1 | Completed | Drug: ABBV-951 | Parkinson's Disease | 16 | 2022-01-18 | 2023-03-17actual | — | 2023-03-24 |
| ANVS | Annovis Bio Inc. | $77M | Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's PatientsNCT04524351results2023-02-28Percentage of Participants With Treatment-Emergent Adverse Events | Phase 1/2 | Completed | Drug: Posiphen, Placebo | Alzheimer Disease, Parkinson Disease | 75 | 2020-08-14 | 2021-08-16actual | — | 2023-02-28 |
| BIVI | BioVie Inc. | $7M | NE3107 Activity and Safety in Patients With Parkinson's Disease Using LevodopaNCT05083260Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours) | Phase 1/2 | Completed | Drug: NE3107, placebo | Parkinson Disease | 46 | 2022-01-04 | 2022-11-21actual | — | 2023-02-08 |
| ABBV | AbbVie | $457.5B | Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal GelNCT04500106observationalParticipant Acceptance of the AbbVie Duodopa Specialist (ADS) Nurse Support and Communication Access | — | Completed | — | Parkinson's Disease | 41 | 2021-04-22 | 2021-10-14actual | — | 2023-02-02 |
| TBPH | Theravance Biopharma | $880M | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03829657results2023-01-20Proportion of Participants With Treatment Failure at Week 6 of RW Treatment Period | Phase 3 | Terminatedsponsor's stated reason: Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169. | Drug: ampreloxetine, Placebo | Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF) | 203 | 2019-02-22 | 2021-11-10actual | — | 2023-01-20 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)NCT04724109observationalNumber of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs) | — | Completed | Drug: Equfina | Parkinson Disease | 1,088 | 2020-10-14 | 2022-10-13actual | — | 2022-12-16 |
| ABBV | AbbVie | $457.5B | Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's DiseaseNCT00660673results2022-12-02Number of Participants With Treatment-emergent Adverse Events | Phase 3 | Completed | Drug: Levodopa-Carbidopa Intestinal Gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J) | Advanced Parkinson's Disease | 262 | 2009-11-13 | 2021-11-30actual | — | 2022-12-02 |
| NBIX | Neurocrine Biosciences | $15.7B | Opicapone Treatment Initiation Open-Label StudyNCT04787965observationalONGENTYS treatment patterns | — | Completed | Drug: Opicapone | Parkinson Disease | 239 | 2021-03-01 | 2022-08-04actual | — | 2022-11-28 |
| ABBV | AbbVie | $457.5B | Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's DiseaseNCT04380142results2022-11-18Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia | Phase 3 | Completed | Drug: ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951 | Parkinson's Disease (PD) | 174 | 2020-10-19 | 2021-09-29actual | — | 2022-11-18 |
| TBPH | Theravance Biopharma | $880M | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)NCT02705755results2022-09-26Part A: Change From Time-matched Placebo in Seated Systolic Blood Pressure (SBP) | Phase 2 | Completed | Drug: TD-9855, Placebo | Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension | 34 | 2017-09-09 | 2018-07-24actual | — | 2022-09-26 |
| 4523.T | Eisai Inc. | $8.7B | A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid CopathologyNCT04764669results2022-09-26Percent Change From Baseline in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP) at Week 9 | Phase 2 | Completed | Drug: E2027 | Lewy Body Disease, Parkinson Disease | 34 | 2021-02-25 | 2021-12-08actual | — | 2022-09-26 |
| AVXL | Anavex Life Sciences Corp. | $297M | OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001NCT04575259Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 2 | Completed | Drug: ANAVEX2-73 | Parkinson Disease Dementia | 132 | 2019-10-10 | 2022-05-31actual | — | 2022-08-01 |
| AZN | AstraZeneca | — | Single Ascending Dose Study of MEDI1341 in Healthy VolunteersNCT03272165Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Phase 1 | Completed | Drug: MEDI1341, Placebo | Parkinson's Disease | 50 | 2017-10-17 | 2021-03-31actual | — | 2022-06-09 |
| AZN | AstraZeneca | — | Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's DiseaseNCT04449484Adverse Events | Phase 1 | Completed | Drug: MEDI1341 · Other: Placebo | Parkinson's Disease | 25 | 2020-08-04 | 2022-01-05actual | — | 2022-06-03 |
| NBIX | Neurocrine Biosciences | $15.7B | Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseNCT03065192Grading of adverse Events/Serious Adverse Events (AE's/SAE's) | Phase 1 | Completed | Drug: VY-AADC01 | Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders | 16 | 2017-05-11 | 2021-08-10actual | — | 2022-03-21 |
| BIIB | Biogen | $31.4B | Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's DiseaseNCT03318523results2021-11-23Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52 | Phase 2 | Terminatedsponsor's stated reason: SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed. | Drug: Placebo, BIIB054 | Parkinson's Disease | 357 | 2018-01-10 | 2020-10-26actual | — | 2022-02-28 |
| ABBV | AbbVie | $457.5B | Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's DiseaseNCT02611713observationalChange in the number of hours spent in OFF time in Arm A | — | Completed | — | Advanced Parkinson's Disease | 213 | 2016-01-04 | 2020-12-24actual | — | 2021-12-15 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's DiseaseNCT04127695Number of Participants with Adverse Events | Phase 1 | Withdrawnsponsor's stated reason: Strategic considerations | Drug: ABBV-0805, Placebo ABBV-0805 | Parkinson's Disease | 0 | 2020-03-03 | 2020-06-16actual | — | 2021-12-15 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineNCT04164758results2021-10-14Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Terminatedsponsor's stated reason: Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons | Drug: Pimavanserin, Quetiapine · Other: Placebo | Parkinson's Disease | 11 | 2019-10-23 | 2020-09-25actual | — | 2021-10-14 |
| HLUN-B.CO | H. Lundbeck A/S | — | Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseNCT03611569Number of patients with Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | Phase 1 | Completed | Drug: Lu AF82422, Placebo | Healthy, Parkinson Disease | 74 | 2018-07-25 | 2021-07-26actual | — | 2021-10-12 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) StudyNCT03152292observationalThe INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) | — | Terminatedsponsor's stated reason: Study follow-up duration impacted by COVID-19pandemic and Sponsor terminated for business reasons | Other: Real-world, non-interventional | Parkinson Disease Psychosis | 764 | 2017-03-30 | 2021-03-08actual | — | 2021-08-06 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's DiseaseNCT03436953Change from Baseline to Day 28 on the MDS-UPDRS Tremor Score as scored by the central rater | Phase 2 | Withdrawnsponsor's stated reason: The program was not initiated nor were any patients ever enrolled. The investigations detailed in the submitted protocol were incorporated into another program. | Drug: CX-8998, Placebo | Parkinson's Disease, Tremor | 0 | Dec 2019 | Sep 2020 | — | 2021-05-28 |
| VTGN | VistaGen Therapeutics, Inc. | $11M | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaNCT04147949Unified Dyskinesia Rating Scale | Phase 2 | Unknown status | Drug: AV-101, Placebo | Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use | 20 | Aug 2022 | Dec 2023 | — | 2021-05-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Parkinson's Disease is matched — 10 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Parkinson's Disease
- Parkinson Disease
- Parkinson's Disease (PD)
- Advanced Parkinson's Disease
- Idiopathic Parkinson's Disease
- Parkinson's Disease Psychosis
- Idiopathic Parkinson Disease
- Parkinson Disease Psychosis
- Parkinson Disease Dementia
- Parkinson's Disease Dementia
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Parkinson's Disease” (a text search, wider than this page)